Safety and antitumor activity of ramucirumab plus pembrolizumab in treatment naïve advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: Preliminary results from a multi-disease phase I study (JVDF)

Authors
Category Primary study
JournalJournal of Clinical Oncology
Year 2018
This article has no abstract
Epistemonikos ID: 8e7d289d51df3a3d990cf5aa9e91b61e2880c5cf
First added on: Feb 09, 2025